

ENDO PHARMACEUTICALS HOLDINGS INC

Form 4

March 14, 2005

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB
Number: 3235-0287Expires: January 31,
2005Estimated average
burden hours per
response... 0.5Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
**KELSO INVESTMENT ASSOC V
L P**

(Last) (First) (Middle)

320 PARK AVENUE,

(Street)

NEW YORK, NY 10022

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
**ENDO PHARMACEUTICALS
HOLDINGS INC [ENDP]**3. Date of Earliest Transaction
(Month/Day/Year)
03/10/20054. If Amendment, Date Original
Filed(Month/Day/Year)5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

☐ Director ☒ 10% Owner
☐ Officer (give title below) ☐ Other (specify
below)6. Individual or Joint/Group Filing(Check
Applicable Line)
☐ Form filed by One Reporting Person
☒ Form filed by More than One Reporting
Person**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)	
			Code	V	Amount	(A) or (D)	Price			
Common Stock, par value \$.01 per share ⁽¹⁾	03/10/2005		X		14,215	D	\$ 2.42	53,064,159	I	By Endo Pharma LLC ⁽²⁾ ⁽³⁾
Common Stock, par value \$.01 per share ⁽¹⁾	03/10/2005		X		1,800	D	\$ 2.42	53,062,359	I	By Endo Pharma LLC ⁽²⁾ ⁽³⁾
Common Stock, par value \$.01 per share	03/10/2005		X		1,579	D	\$ 2.42	53,060,781	I	By Endo Pharma LLC ⁽²⁾ ⁽³⁾

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

Common Stock, par value \$.01 per share	03/10/2005	X	1,495	D	\$ 3.42	53,059,286	I	By Endo Pharma LLC <u>(2)</u> <u>(3)</u>
Common Stock, par value \$.01 per share	03/10/2005	X	4,860	D	\$ 2.42	53,054,426	I	By Endo Pharma LLC <u>(2)</u> <u>(3)</u>
Common Stock, par value \$.01 per share	03/10/2005	X	5,205	D	\$ 2.42	53,049,221	I	By Endo Pharma LLC <u>(2)</u> <u>(3)</u>
Common Stock, par value \$.01 per share	03/10/2005	X	1,875	D	\$ 2.42	53,047,345	I	By Endo Pharma LLC <u>(2)</u> <u>(3)</u>
Common Stock, par value \$.01 per share	03/10/2005	X	673	D	\$ 3	53,046,672	I	By Endo Pharma LLC <u>(2)</u> <u>(3)</u>
Common Stock, par value \$.01 per share	03/10/2005	X	800	D	\$ 2.42	53,045,872	I	By Endo Pharma LLC <u>(2)</u> <u>(3)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Call Option (obligation to sell)	\$ 2.42	03/10/2005		X			14,215	11/29/2004	08/26/2007	Common Stock	14,215

Call Option (obligation to sell)	\$ 2.42	03/10/2005	X	1,800	12/15/2004	08/26/2007	Common Stock	1,800
Call Option (obligation to sell)	\$ 2.42	03/10/2005	X	1,579	12/15/2004	08/26/2007	Common Stock	1,579
Call Option (obligation to sell)	\$ 3.42	03/10/2005	X	1,495	12/15/2004	08/26/2007	Common Stock	1,495
Call Option (obligation to sell)	\$ 2.42	03/10/2005	X	4,860	12/15/2004	08/26/2007	Common Stock	4,860
Call Option (obligation to sell)	\$ 2.42	03/10/2005	X	5,205	12/15/2004	08/26/2007	Common Stock	5,205
Call Option (obligation to sell)	\$ 2.42	03/10/2005	X	1,875	12/15/2004	08/26/2007	Common Stock	1,875
Call Option (obligation to sell)	\$ 3	03/10/2005	X	673	12/15/2004	08/26/2007	Common Stock	673
Call Option (obligation to sell)	\$ 2.42	03/10/2005	X	800	12/15/2004	08/26/2007	Common Stock	800

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
KELSO INVESTMENT ASSOC V L P 320 PARK AVENUE NEW YORK, NY 10022		X		
NICKELL FRANK T C/O KELSO & COMPANY 320 PARK AVENUE		X		

NEW YORK, NY 10022

BERNEY PHILIP E
C/O KELSO & COMPANY
320 PARK AVENUE
NEW YORK, NY 10022

X

BYNUM FRANK K
C/O KELSO & COMPANY
320 PARK AVENUE
NEW YORK, NY 10022

X

WALL THOMAS R IV
C/O KELSO & COMPANY
320 PARK AVENUE
NEW YORK, NY 10022

X

GOLDBERG MICHAEL B
C/O KELSO & COMPANY
320 PARK AVENUE
NEW YORK, NY 10022

X

X

MATELICH GEORGE E
C/O KELSO & COMPANY
320 PARK AVENUE
NEW YORK, NY 10022

X

SCHUCHERT JOSEPH S
C/O KELSO & COMPANY
320 PARK AVENUE
NEW YORK, NY 10022

X

WAHRHAFTIG DAVID I
C/O KELSO & COMPANY
320 PARK AVENUE
NEW YORK, NY 10022

X

X

Lazar Michael B
320 PARK AVENUE
NEW YORK, NY 10022

X

Signatures

James J.
Connors, II

03/14/2005

**Signature of
Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Kelso Investment Associates V, L.P. ("KIA V") is the designated filer.

(2) KIA V may be deemed to share beneficial ownership of shares of Common Stock owned of record by Endo Pharma LLC by virtue of its status as a member of Endo Pharma LLC. KIA V shares investment and voting power along with the other members of Endo Pharma LLC with respect to securities owned by Endo Pharma LLC, but disclaims beneficial ownership of such securities except to the extent of

Edgar Filing: ENDO PHARMACEUTICALS HOLDINGS INC - Form 4

its pecuniary interest.

- (3) Each individual reporting person may be deemed to share beneficial ownership of shares of Common Stock owned of record by KIA V, by virtue of his status as a general partner of the general partner of KIA V, and each individual shares investment and voting power along with the other general partners of KIA V, but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.